2. OPPORTUNITY
According to Chinese Business Association reported that
in 2007, with erythromycin-based macrolide antibiotics,
total global sales of more than 90 million sales of
clarithromycin in the global market has risen to 15 billion
U.S. dollars, accounting for international macrolide
antibiotics 18% of total sales, of which Abbott's patentname drugs clarithromycin only half of the remaining
shares are contributed by imitation. Because
clarithromycin Preparation Popular hospital in the
country, the domestic pharmaceutical manufacturers
spotted the opportunity to develop the production of
clarithromycin
Join us to take NanoClarithromycin to Clinic
3. What is Needed?
Emulsifier is an egg phosphatide. No Need of It!
Bio-available at all pH in all parts of digestive system in oral
delivery formulations. pH independence needed.
Soybean oil, an egg phosphatide, oleic acid, hexanoic acid and
glycerin elimination fro formulations. Zero Need Of It!
An effective, safe and most inexpensive nanomedicine for
Clarithromycin. It is Needed!
To eliminate acids from formulation. Take It out !
5. Issues & Needs
It has been found that erythromycin fat emulsions are
locally non-irritative. The antibiotic clarithromycin,
however, has a low solubility in fat emulsions even in the
presence of oils, and will precipitate out of such
emulsions. It has heretofore not been possible to
solubilize clarithromycin so as to achieve stable injectable
compositions at concentrations which are high enough for
therapeutically effective pharmaceutical purposes.
There is a continuing need for stable injectable
compositions of clarithromycin at therapeutically
acceptable concentrations that do not cause severe pain
at the injection site.
A genuine Project for investment
6. What is new?
Present invention releases drug at all pH and faster
than any existing formulation.
Invention for nanomedicine
Patented nanomedicine to prevent generic cliff
Most inexpensive manufacturing of nanomedicines.
Your manufacturing set-up remains same.
12. % of strains
NCCLS
Susceptible breakpoint
PK/PD
H. influenzae
Clarithromycin
S. pneumoniae
Clarithromycin
0.25
8
ALL
ORGANISMS
0.25
PK/PD breakpoint based
on current approved
dosing regimens
70
60
M. catarrhalis
50
40
S. pneumoniae
30
20
H. influenzae
10
0
0.03
0.12
0.5
2
MIC in ug/mL
Alexander Project USA 2000
8
32
Solubility is a genuine need
Resolved by Meda Biotech llc.
13. Technology
1.
2.
3.
4.
5.
6.
New molecule MR007 for nanoparticle
MR007 provides synergistic
Lowest manufacturing cost
Strong patent
No need of existing facility change
No need to hire new staff
1.
